Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Wednesday, December 25, 2024 in observance of Christmas and Wednesday, January 1, 2025 in observance of New Year's Day. Have a healthy, happy holiday.

Hide
Quest Diagnostics

Cardiometabolic disease

Know the early warning signs of metabolic syndrome—a growing problem

Metabolic syndrome has become increasingly common. This collection of risk factors includes high blood sugar, high triglycerides, high blood pressure, low LDL levels, and large waist circumference.1

More than a third of adults in the United States meet the criteria for metabolic syndrome.2 Patients who have metabolic syndrome are at higher risk of diabetes, coronary heart disease, cancer, stroke, and other chronic conditions.

Quest Diagnostics offers a full range of testing options to evaluate metabolic and cardiovascular risk, allowing you to take action to help patients prevent or delay the onset of chronic conditions and prevent adverse events.

 

Defining the intersection of chronic conditions: a prevention-focused approach to cardiometabolic disease

With more people at risk for cardiovascular disease than ever before, the Quest Cardiometabolic Center of Excellence™ at Cleveland HeartLab® is advancing a prevention-focused approach for heart disease and associated metabolic conditions.

Cardiovascular disease (CVD) is strongly associated with type 2 diabetes (T2DM), chronic kidney disease (CKD), and nonalcoholic fatty liver disease (NAFLD). Through significant investments in novel technology, the Cleveland HeartLab® is fostering innovation to detect these conditions in their early stages, providing the opportunity for stage-targeted intervention and improved clinical outcomes.

  • Cardiovascular disease is the leading cause of death for individuals who have T2DM,3 stage 4-5 CKD,4 and NAFLD.5
  • Those who have T2DM have a 2 to 3 times higher risk of fatal coronary heart disease.6
  • Nearly 40% of persons who have diabetes and more than 30% of those who have hypertension also have CKD.7 The leading causes of end-stage renal disease are diabetes and hypertension.8
  • More than 75% of those who have T2DM have NAFLD.9

 

A comprehensive range of testing

Know the risk for cardiovascular disease

Cardiovascular disease continues to be the leading cause of death in the US.4 Guidelines are evolving to implement new kinds of cardiovascular testing that may help save millions of lives. Quest Diagnostics is at the forefront, dedicated to incorporating advanced testing methods that provide accurate results.

Learn more about Quest cardiovascular disease testing

Identify diabetes & pre-diabetes sooner

In both pre-diabetes and diabetes, diagnosis is a necessary first step to taking preventive action in the form of medication and lifestyle changes such as exercise, weight reduction, and healthy eating.

Effectively monitor and manage your patients with pre-diabetes and diabetes to help them delay or avoid complications with our comprehensive panels. Our testing is aligned with American Diabetes Association guidelines, making it easy for you to meet key performance measures and keep your patients on track with recommended testing.10-12

Learn more about Quest diabetes and pre-diabetes testing

Take action to help prevent chronic kidney disease

Chronic kidney disease is frequently caused by high blood pressure and diabetes. Careful control of high blood pressure and blood sugar can slow or prevent the progression of kidney disease. Assess kidney function and damage with help from Quest’s guidelines-based testing for a more complete picture of your patient’s kidney health.

Learn more about Quest chronic kidney disease testing

Get ahead of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) is a liver condition associated with obesity, diabetes, and dyslipidemia. In some patients, NAFLD is accompanied by varying degrees of inflammation and fibrosis—nonalcoholic steatohepatitis (NASH)—which may progress to cirrhosis and attendant complications.

In recent studies, NAFLD has been shown to predict the development of type 2 diabetes, and vice versa,13 while some complications of diabetes may be directly linked to NAFLD.14

Quest’s testing options allow you to effectively diagnose, track, and treat these significant cardiometabolic conditions. 

Learn more about Quest NAFLD and NASH testing

The power of Quest Cardiometabolic Center of Excellence™ at Cleveland HeartLab®

Comprehensive range of testing

With Quest on your side, you get access to more than 3,500 tests, ranging from routine screening to highly specialized testing, including molecular genetics and esoteric tests. Beyond testing, we offer a broad array of integrated healthcare information services that deliver the insights you need to optimize patient diagnosis, treatment, and management.

Access to medical experts

We are committed to helping you deliver the best possible care to your patients. That’s why Quest has over 600 MDs, PhDs, and genetic counselors across the country who are available for consultations to help advise you on test selection and results interpretation.

Patient adherence tools

Patient adherence and compliance are critical, no matter what the condition. We offer an array of simple and effective tools to help your patients stay organized and motivated. Quest’s 4myheart® program is a personalized care platform—based on findings from our Cardio IQ Test—designed to help patients improve and maintain their cardiovascular and metabolic health.

Advanced cardiovascular testing

Quest’s cardiovascular testing options include comprehensive lipid testing as well as advanced inflammatory marker testing. Through significant investments in novel technology, we’re helping to foster innovation to detect cardiometabolic conditions in their early stages and improve clinical outcomes.

This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.


References

  1. What is metabolic syndrome? American Heart Association. Available at: https://www.heart.org/en/health-topics/metabolic-syndrome/about-metabolic-syndrome. Accessed September 1, 2021.
  2. Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Prev Chronic Dis. 2017;14:160287.
  3. Einarson,TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(83). doi: 10.1186/s12922-018-0728-6
  4. Benjamin EJ, Virani SS, Callaway CW, et al. On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67-e492. doi:10.1161/CIR.0000000000000558
  5. Golabi P, Fukui N, Paik J, et al. Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2019;3(8):1050-1060. doi: 10.1002/hep4.1387
  6. Fox CS, Sullivan L, D’Agostino R, et al. The significant effect of diabetes duration on coronary heart disease mortality. Diabetes Care. 2004;27(3):704-708. doi:10.2337/diacare.27.3.704
  7. Penn MS, Klemes AB. Multimarker approach for identifying and documenting mitigation of cardiovascular risk. Future Cardiol. 2013;9(4):497-506. doi:10.2217/fca.13.27
  8. Ikonomidis I, Mihalakeas CA, Lekakis J, et al. Multimarker approach in cardiovascular risk prediction. Dis Markers. 2009;26(5-6):273-285. doi:10.3233/DMA-2009-0633
  9. Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011; 9(3): 321–328. doi:10.1586/erc.11.15
  10. Standards of Medical Care in Diabetes—2014. Diabetes Care. 2014;37 (suppl 1):S14-S80. Page S42-S43.
  11. National Committee for Quality Assurance. What is the current state of quality of care in diabetes? Available at: www.ncqa.org/PublicationsProducts/OtherProducts/QualityProfiles/FocusonDiabetes/WhatistheCurrentStateofQualityofCare.aspx. Accessed September 1, 2021.
  12. Medicare.gov. Star ratings. Available at www.medicare.gov/find-a-plan/staticpages/rating/planrating-help.aspx. Accessed September 1, 2021.
  13. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-2023.
  14. Williams KH, Shackel NA, Gorrell MD, et al. Diabetes and nonalcoholic fatty liver disease: A pathogenic duo. Endocr Rev. 2013;34:84-129.

During the COVID-19 health crisis, fast action and trusted information matter more than ever.

Find out what's happening

Learn More

About our tests

Resources

CKD: Laboratory Support of Diagnosis and Management Primary Insights Article

How to read your patient’s Cardio IQ® report

Diabetes portfolio brochure

TMAO brochure

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.